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This study aimed to identify a single miRNA or miR (microRNA) which regulates the three
insulin-like growth factor-2-mRNA-binding proteins (IGF2BP1, 2 and 3). Bioinformatics predicted
miR-1275 to simultaneously target the three IGF2BPs, and screening revealed miR-1275 to be
underexpressed in hepatocellular carcinoma (HCC) tissues. Transfection of HuH-7 cells with
miR-1275 suppressed IGF2BPs expression and all three IGF2BPs were conﬁrmed as targets of
miR-1275. Ectopic expression of miR-1275 and knockdown of IGF2BPs inhibited malignant cell
behaviors, and also reduced IGF1R protein and mRNA. Finally IGF1R was validated as a direct target
of miR-1275. These ﬁndings indicate that the tumor-suppressor miR-1275 can control HCC tumor
growth partially through simultaneously regulating the oncogenic IGF2BPs and IGF1R.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The pathogenesis of hepatocellular carcinoma (HCC) is multi-
faceted and complex, involving irregularities in several important
cell signaling pathways including the insulin-like growth factor
(IGF) axis. This pathway is activated when IGF-1 or IGF-2 bind tothe IGF-1 receptor (IGF1R), and leads to a multitude of effects
that modulate cell growth, differentiation, proliferation, and
apoptosis [1].
The bioavailability of IGF-2, and hence activation of the IGF axis,
can be post-transcriptionally ﬁne-tuned by IGF-2-mRNA-binding
proteins (IGF2BPs) 1, 2 and 3 [2,3]. The IGF2BPs associate with
newly transcribed target mRNAs forming stable cytoplasmic com-
plexes which have been suggested to enhance [4] or inhibit [2]
translation of the mRNA, prevent the premature degradation of
the mRNA by limiting its release or protecting it from the decaying
actions of endonucleases or microRNAs [5–8], or assist in the
long-distance transport and storage of target transcripts, especially
under stress conditions [9]. These oncofetal cytoplasmic mRNA-
binding proteins have been implicated in several oncogenic events
in many cancers [10]. They are re-expressed in various tumors,
including HCC, where their high expression is correlated with
tumor invasion, early recurrence, and poor prognosis [11–15].
Moreover, IGF2BPs may play a detrimental role in malignant
transformation of the liver as they have been reported to induce
lipogenesis and steatohepatitis [16] and promote non-alcoholic
fatty liver disease, which are well-recognized risk factors for HCC
[17]. In addition, the IGF2BPs have been linked to cancer at the
Table 1
Characteristic features and clinical parameters of study-recruited non-metastatic
hepatocellular carcinoma (HCC) patients and healthy liver donors.
HCC and cirrhotic patients
Mean age 49 ± 13.5
Sex: male/female 21/1
History of alcohol abuse None
Aspartate aminotransferase (U/L) 100.5 ± 65.8
Alanine aminotransferase (U/L) 85.6 ± 95.6
Alkaline phosphatase (U/L) 110.2 ± 60.7
Serum albumin (g/dL) 4.6 ± 1.5
Serum alpha-fetoprotein (ng/mL) 155.7 ± 22.3
HCV statusa 100% (22/22 HCC patients)
HBV statusb 18.2% (4/22 HCC patients)
Healthy controls (liver donors)
Mean age 31 ± 10.5
Sex: male/female 13/6
History of alcohol abuse None
Diabetic None
Hypertensive None
HCV statusa None
HBV statusb None
a HCV status was determined using anti-HCV antibody and/or HCV viral RNA
quantiﬁcation.
b HBV status was determined using anti-HBc and anti-HBs antibodies and by
detection of HBsAg.
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were reported to control the post-transcriptional fate of numerous
oncogenic transcripts such as IGF-2, MYC, KRAS, and MKI67
[12,14,18–20].
Studies regarding the regulation of the oncofetal IGF2BPs by
microRNAs – a class of small endogenous non-coding RNA mole-
cules known to post-transcriptionally control gene expression
[21] – are scarce. In fact, to date, to the best of our knowledge only
miR-494 [22], the microRNAs of the let-7 family [23], and recently
miR-625 [24] have been shown to regulate IGF2BP1, and only
let-7b [25] and recently miR-216b [26] are known to target
IGF2BP2, while the regulation of IGF2BP3 by microRNAs has not
been published as of yet. MicroRNAs are often viewed as master
regulators of the human genome, and since a single microRNA
can potentially control the expression of multiple genes, these
short oligonucleotide sequences have quickly been recognized forTable 2
Assessment of liver disease of each study-recruited non-metastatic hepatocellular carcino
Patients Number of focal lesions Size of focal lesions
Patient 1 3 focal lesions 1.5 cm, 1 cm, 1 cm
Patient 2 Unifocal 2.5 cm
Patient 3 3 focal lesions 2 cm, 2.5 cm, 3 cm
Patient 4 3 focal lesions 2 cm, 2 cm, 3.5 cm
Patient 5 Unifocal 1.5  2 cm
Patient 6 3 focal lesions 3  4 cm, 1 cm, 1 cm
Patient 7 Unifocal 4 cm
Patient 8 3 focal lesions 4 cm, 1 cm, 1 cm
Patient 9 3 focal lesions 1 cm, 1 cm, 1.5 cm
Patient 10 Unifocal 2.5 cm
Patient 11 2 focal lesions 1 cm, 1.7 cm
Patient 12 3 focal lesions 1 cm, 1 cm, 1 cm
Patient 13 Unifocal 3 cm
Patient 14 3 focal lesions 3 cm, 1.5 cm, 2 cm
Patient 15 3 focal lesions 1 cm, 1 cm, 4 cm
Patient 16 2 focal lesions 3 cm, 1.5 cm
Patient 17 2 focal lesions 1.5 cm, 3 cm
Patient 18 3 focal lesions 2.5 cm, 2.5 cm, 1.5 cm
Patient 19 3 focal lesions 1.5 cm, 1 cm, 1 cm
Patient 20 Unifocal 2 cm
Patient 21 Unifocal 1.5 cm
Patient 22 3 focal lesions 3 cm, 2.5 cm, 1 cm
a MELD: Model for End-stage Liver Disease score.
b PT-INR: international normalized ratio for prothrombin time.their therapeutic value and have already entered clinical trials
(https://clinicaltrials.gov/ct2/show/NCT01829971) [27,28].
Therefore the current study sought to identify a single
microRNA which simultaneously targets all three oncogenic
IGF2BPs, and evaluate its consequent impact on tumor growth in
HCC. Through bioinformatics prediction software, gain- and
loss-of-function analyses using microRNA mimics and inhibitors,
and luciferase reporter assays we determined that miR-1275 is a
key regulator of hepatocarcinogenesis by targeting several
oncogenic members of the IGF axis.
2. Materials and methods
2.1. Patients
HCC and cirrhotic tissues from 22 HCC patients and normal liver
tissues from 19 donors were obtained, with prior consent, during
liver transplantation surgery at the Kasr El-Aini Hospital in Cairo,
Egypt. Table 1 shows the clinical data of all study-recruited
individuals. Notably, 100% of HCC patients tested positive for the
presence of hepatitis C virus (HCV) infection. The assessment of
liver disease in each patient is shown in Table 2. The study was
approved by the appropriate ethical committees and all
experiments were in accordance to the ethical standards of the
declaration of Helsinki.
2.2. Bioinformatics
Bioinformatics algorithms microrna.org (http://www.microrna.
org), DIANA Lab (http://www.diana.cslab.ece.ntua.gr/), and Target
Scan (http://www.targetscan.org/) were used to predict
microRNAs which can simultaneously target the 30untranslated
regions (30UTRs) of IGF2BP1, IGF2BP2, and IGF2BP3. These
algorithms were also used to predict whether miR-1275 may bind
to the 30UTR of IGF1R.
2.3. Cell culture and oligonucleotide transfection
HuH-7 cells were cultured in DMEM supplemented with 10%
FBS, 1% penicillin/streptomycin/mycozap (Lonza, Switzerland).
Cells were transfected with mimics or inhibitors of miR-1275, orma (HCC) patient.
MELDa score Child-pugh score PT-INRb
11 C 1.4
15 C10 1.6
10 C11 2.4
10 C 2
16 C 1.4
12 B 1.5
11 B7 1.5
8 A5 1.3
17 C 1.5
10 B8 1.4
15 B8 1.4
17 C11 1.8
13 B7 1.6
15 B 1.6
12 B7 1.14
19 C12 1.9
16 C10 1.55
9 B7 1.18
11 B8 1.19
18 C 1.7
17 C 1.55
12 B 1.6
Table 3
Forward (F) and reverse (R) primer sequences for wild-type and mutant 30UTR
constructs.
IGF2BP1 F 50-CAGCTTTTTTTTCCCCCATAAATAAT-30
Wild-type
30UTR
R 50-CTAGATTATTTATGGGGGAAAAAAAAGCTGAGCT-30
IGF2BP1 F 50-CAGCTTTTTTTAAATAAT-30
Mutant 30UTR R 50-CTAGATTATTTAAAAAAAGCTGAGCT-30
IGF2BP2 F 50-CTCTACGCACCCCCCCCCCCCCAGGCAAAGT-30
Wild-type
30UTR
R 50-
CTAGACTTTGCCTGGGGGGGGGGGGGTGCGTAGAGAGCT-30
IGF2BP2 F 50-CTCTACGCACGGCAAAGT-30
Mutant 30UTR R 50-CTAGACTTTGCCGTGCGTAGAGAGCT-30
IGF2BP3 F 50-CAATTCTTCTTAATATTCCCCCATAATGCCT-30
Wild-type
30UTR
R 50-
CTAGAGGCATTATGGGGGAATATTAAGAAGAATTGAGCT-30
IGF2BP3 F 50-CAATTCTTCTTAATATAATGCCT-30
Mutant 30UTR R 50-CTAGAGGCATTATATTAAGAAGAATTGAGCT-30
IGF1R F 50-CTTTTTGGGTTTTTTTTCCCCCAAACATTTT-30
Wild-type
30UTR
R 50-
CTAGAAAATGTTTGGGGGAAAAAAAACCCAAAAAGAGCT-30
IGF1R F 50-CTTTTTGGGTTTTTTAACATTTT-30
Mutant 30UTR R 50-CTAGAAAATGTTAAAAAACCCAAAAAGAGCT-30
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using HiPerFect Transfection Reagent (Qiagen), according to the
manufacturer’s protocol. Mock cells are cells exposed to transfec-
tion reagent only.Fig. 1. Expression proﬁle of miR-1275 in liver tissues and impact of miR-1275 on IGF2BP
miR-1275 was investigated in healthy, cirrhotic, and HCC liver tissues using RTqPCR. Ma
*P < 0.05. HuH-7 cells were transfected with miR-1275 mimics or inhibitors, and the relat
using RTqPCR, relative to mock untransfected cells. Data are expressed as the mean ± SEM
*P < 0.05.2.4. microRNA and mRNA extraction and quantiﬁcation from liver
tissues and HuH-7 cell line
Total mRNA and microRNAs were extracted from liver speci-
mens using mirVana microRNA Isolation Kit (Ambion, USA),
according to the manufacturer’s protocol. HuH-7 cells were har-
vested using BIOZOL RNA Extraction Reagent (Bioer Technology,
China). Complementary DNA was generated using reverse tran-
scription (Applied Biosystems, USA). Relative expression of
miR-1275 was normalized to RNU6B in each sample, while
IGF2BP1, IGF2BP2, IGF2BP3, and IGF1R relative expressions were
normalized to beta-2 microglobulin (B2M), and quantiﬁed using
TaqMan Real-time quantitative polymerase chain reaction
(RTqPCR) (Applied Biosystems). Relative expression was calculated
using the 2-DDCT method.
2.5. BrdU cell proliferation assay
Forty-eight hours after transfection of HuH-7 cells, proliferation
was assessed according to manufacturer’s protocol using the BrdU
Cell Proliferation ELISA kit (Roche Applied Biosystems, Germany)
and luminescence, expressed in relative light units per second,
was measured.
2.6. MTT viability assay
Forty-eight hours post-transfection of HuH-7 cells 4,5-dimethyl
thiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) was added.1, IGF2BP2, and IGF2BP3 mRNA expression in HuH-7 cell line (A) The expression of
nn Whitney test was performed to compare each two groups. ***P < 0.001, **P < 0.01,
ive expression of (B) IGF2BP1, (C) IGF2BP2, and (D) IGF2BP3 mRNA was determined
. Student’s t test was performed to compare each two groups. ***P < 0.001, **P < 0.01,
Fig. 2. Luciferase reporter assays to validate the targeting of IGF2BP1, IGF2BP2, and
IGF2BP3 30UTRs by miR-1275. For each target gene, HuH-7 cells were co-transfected
with miR-1275 mimics or inhibitors and either empty pmiRGLO vector, or the wild-
type (WT) construct, or the mutant (MUT) construct for (A) IGF2BP1, (B) IGF2BP2,
and (C) IGF2BP3. Schematic illustration of sequence alignments between 30UTRs of
the target genes and seed-sequence of miR-1275 are shown above each corre-
sponding graph. Data are expressed as the mean ± SEM. Student’s t test was
performed to compare each two groups. ***P < 0.001, **P < 0.01, *P < 0.05.
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solution and optical density was measured at 550 nm and relative
viability was calculated.2.7. Colony-forming assay
HuH-7 cells were seeded at 1000 cells/well, then transfected
with oligonucleotides. Twenty-four hours post-transfection, cells
were detached and imbedded in a top layer of 0.36% soft agarose
overlaid on a 0.76% agarose bottom layer. The 6-well plates were
incubated for two weeks to colonize.
2.8. Wound-healing assay
Forty-eight hours post-transfection of HuH-7 cells, 5 scratch-
es/well were made, then cells were then incubated with medium
supplemented with antibiotic and 1% FBS for 24 h. Randomly cho-
sen ﬁelds were photographed under a microscope (AXIO observer
A1, ZEISS, Germany) at 10X magniﬁcation and areas of scratches
were recorded at time 0 h and 24 h and percentages of wound
closures were calculated.
2.9. Reporter constructs and Luciferase assay
For wild-type constructs (WT), the miR-1275 binding regions in
the 30UTRs of the longest isoforms of IGF2BP1, IGF2BP2, IGF2BP3, or
IGF1R were inserted in the pmirGLO Dual-Luciferase microRNA
Target Expression Vector (Promega, USA). In addition, mutant con-
structs (MUT) were designed, as shown in Table 3; the sequences
in bold indicate the binding region nucleotides which were deleted
to form the mutant constructs. HuH-7 cells were transfected with
2 lg of the constructs or empty pmirGLO vector using SuperFect
(Qiagen) then co-transfected 24 h later with miR-1275 mimics or
inhibitors using HiPerFect (Qiagen). Relative luciferase activity
was measured after 48 h by the Luciferase Reporter Assay Kit
(Biovision, USA).
2.10. Flow cytometric analysis
At 72 h post-transfection cell aliquots were incubated with pri-
mary antibody (IGF1Ra Antibody (1H7), Santa Cruz Biotechnology,
USA) for 20 min followed by washing with PBS. Cells were
incubated with secondary antibody (goat anti-mouse IgG-FITC,
Santa Cruz Biotechnology) for 20 min in the dark, then washed
and resuspended in PBS, and analyzed immediately using a
Coulter Epics XL ﬂow cytometer (Beckman-coulter, Florida, USA).
The mean ﬂuorescence signal intensity (MFI) was analyzed using
WinMDI software (http://facs.scripps.edu/soft-ware.htm) supplied
by Dr. Joe Trotter, Salk Institute (La Jolla, CA, USA) and calculated as
the percentage of that of mock cells.
2.11. Statistical analysis
All experiments were performed in triplicates and repeated at
least three times. The data were expressed as the mean ± standard
error of the mean (SEM). All analyses, unless otherwise stated,
were performed using GraphPad Prism version 5 and a
two-tailed value of P < 0.05 was considered statistically signiﬁcant
with Student’s t-test.
3. Results
3.1. Expression of miR-1275 is downregulated in cirrhotic and
cancerous liver tissues
Bioinformatics was used to identify microRNAs which could
simultaneously target IGF2BP1, IGF2BP2, and IGF2BP3 transcripts,
Fig. 3. Impact of miR-1275 on viability, proliferation, migration, and clonogenicity of HuH-7 cell line. HuH-7 cells were transfected with miR-1275 mimics or inhibitors. Also,
oncofetal IGF2BP1, IGF2BP2, and IGF2BP3 were silenced in HuH-7 cells using speciﬁc siRNAs. In all experiments, data are expressed as the mean ± SEM and Student’s t test
was performed to compare each two groups, where ***P < 0.001, **P < 0.01, *P < 0.05. (A) MTT assay for cellular viability, (B) BrdU incorporation assay for cellular proliferation,
(C) wound-healing assay for tumor cell migration, (D) colony-forming assay for clonogenicity were performed.
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investigate the expression of miR-1275 in liver cancer, RTqPCR
was performed in 22 HCC and cirrhotic tissues and 19 healthy
liver tissues. Screening revealed that both cirrhotic (P = 0.0013)
and HCC (P < 0.0001) tissues of HCC patients have markedly
lower expression of miR-1275 than healthy liver tissues
from liver donors suggesting that miR-1275 becomes
underexpressed during the malignant transformation of liver
tissue (Fig. 1A).
3.2. Overexpression of miR-1275 decreases IGF2BP1, IGF2BP2, and
IGF2BP3 mRNA expression in HuH-7 cell line
Gain- and loss-of-function experiments were performed to
determine the effect of miR-1275 on the IGF2BPs. Ectopic
expression of miR-1275 resulted in a noticeable decrease in
IGF2BP1, IGF2BP2, and IGF2BP3 mRNA levels compared to mock
cells (P = 0.0037, P = 0.0014, and P = 0.0119, respectively)
(Fig. 1B–D). On the other hand, inhibition of miR-1275 showed
IGF2BP1, IGF2BP2, and IGF2BP3 expression levels comparable to
those observed in mock cells. Nonetheless these ﬁndings demon-
strate that, similar to siRNAs against IGF2BP1, IGF2BP2, andIGF2BP3 (P < 0.0001, P < 0.0001, and P = 0.0001, respectively),
miR-1275 can dramatically diminish the expression of the
IGF2BPs (Fig. 1).
3.3. IGF2BP1, IGF2BP2, and IGF2BP3 are direct targets of miR-1275
To conﬁrm that miR-1275 directly targets IGF2BP1, IGF2BP2,
and IGF2BP3, the binding region from the 30UTR of each target
gene was inserted downstream to the luciferase reporter gene
in pmiRGLO vector. A mutant construct for each binding site
was also prepared in which the predicted binding sequence
had been deleted. In a set of cells, empty pmiRGLO vector
was also transfected as a control to ensure that miR-1275
oligonucleotides have no effect on the vector itself. For
IGF2BP1, IGF2BP2, and IGF2BP3 WT constructs, luciferase
activity was markedly inhibited when cells were co-transfected
with miR-1275 mimics (P = 0.0313, P = 0.0035, and P = 0.0021,
respectively) (Fig. 2A–C, respectively), indicating direct targeting
and transcriptional inhibition of the target genes by miR-1275.
On the other hand, luciferase activity showed no change
when WT constructs were co-transfected with miR-1275
inhibitors. Moreover, the effect was abolished when the
Fig. 4. Impact of IGF2BP knockdown and miR-1275 on IGF1R protein expression in HuH-7 cell line. (A) HuH-7 cells were transfected with speciﬁc siRNAs against each of the
three IGF2BPs and the level of IGF1R protein was evaluated using ﬂow cytometry. (B) The mean ﬂuorescence intensity (MFI) of knockdown cells compared to mock cells as
measured by ﬂow cytometry. (C) HuH-7 cells were transfected with miR-1275 mimics or inhibitors and the level of IGF1R protein was evaluated using ﬂow cytometry.
(D) The MFI of cells transfected with miR-1275 mimics or inhibitors was compared to mock cells as measured by ﬂow cytometry. All data are expressed as the mean ± SEM.
Student’s t test was performed to compare each two groups. ***P < 0.001, **P < 0.01, *P < 0.05.
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(Fig. 2). These ﬁndings assert the necessity of the binding region
nucleotides for the efﬁcient targeting of these genes by
miR-1275.
3.4. Overexpression of miR-1275 inhibits viability, proliferation,
wound-healing, and clonogenicity of HuH-7 cell line
Since the role of miR-1275 in hepatocarcinogenesis has never
been explored, MTT, BrdU, migration, and colony-formation assays
were performed to evaluate its overall effect on various character-
istic properties of tumor cells. MiR-1275 or siRNAs against IGF2BPs
were transiently transfected in HuH-7 cells. Compared to mock
cells, ectopic expression of miR-1275 signiﬁcantly suppressed
cellular viability (P < 0.0001), proliferation (P = 0.0038),
wound-healing (P = 0.0362), and clonogenicity (P = 0.0005)
(Fig. 3A–D). As expected, siRNAs against IGF2BP1, IGF2BP2, and
IGF2BP3 also drastically decreased the viability (P = 0.0256,
P = 0.0364, and P = 0.0007, respectively), proliferation (P = 0.0266,
P < 0.0001, and P = 0.0056, respectively), wound-healing
(P < 0.0001, P = 0.0003, and P = 0.0004, respectively), and clono-
genicity (P = 0.0005, P = 0.0008, and P = 0.0007, respectively) of
HuH-7 cells compared to mock cells (Fig. 3). In contrast, cells trans-
fected withmiR-1275 inhibitors showed properties similar to those
of mock cells (Fig. 3). Taken together, these results emphasize the
impact of miR-1275 on hepatocarcinogenesis through its effect on
the IGF2BPs.3.5. IGF2BP knockdown and miR-1275 overexpression decrease IGF1R
protein expression in HuH-7 cell line
Previous studies have indicated that the IGF2BPs play a role in
regulating IGF-2 transcripts [2–4], butwhether the IGF2BPs can con-
trol the post-transcriptional fate of the IGF1RmRNA in humans has
notbeen investigated. Flowcytometric analysis revealed that silenc-
ing of IGF2BP1, IGF2BP2, and IGF2BP3 in HuH-7 cells all signiﬁcantly
reduced IGF1R protein levels compared to mock cells (P = 0.0405,
P = 0.0012, and P = 0.0043, respectively) (Fig. 4A and B). Since
ectopic expression of miR-1275 suppressed the IGF2BPs, it was
intriguing to discover whether this microRNA would have similar
effects on IGF1R. Indeed, forcing the expression of miR-1275 caused
a considerable decrease in IGF1R protein compared to mock cells
(P = 0.05) (Fig. 4C and D).
3.6. IGF2BP knockdown and miR-1275 overexpression decrease IGF1R
transcript levels in HuH-7 cell line
Interestingly, transfection of siRNAs against IGF2BP1, IGF2BP2,
and IGF2BP3 all led to a marked decrease in IGF1R mRNA levels
compared to mock cells (P < 0.0001, P < 0.0001, and P = 0.0064,
respectively) (Fig. 5A). Transfection of miR-1275 mimics also
markedly decreased IGF1R mRNA levels compared to mock cells
(P = 0.0023). On the other hand, cells transfected with miR-1275
inhibitors showed IGF1R transcript levels similar to mock cells
(Fig. 5B). The observation revealed that miR-1275 attenuated the
Fig. 5. Impact of IGF2BP knockdown and miR-1275 on IGF1R mRNA expression in HuH-7 cell line and validation of IGF1R as a direct target of miR-1275. (A) The relative
expression of IGF1R mRNA was determined using RTqPCR in HuH-7 cells transfected with speciﬁc siRNAs against each of the IGF2BPs relative to mock cells. (B) The relative
expression of IGF1R mRNA was determined in cells transfected with miR-1275 mimics or inhibitors relative to mock cells. (C) Luciferase reporter assay was used to validate
the targeting of IGF1R 30UTR by miR-1275. HuH-7 cells were co-transfected with miR-1275 mimics or inhibitors and either empty pmiRGLO vector, or the wild-type (WT)
IGF1R 30UTR construct, or the mutant (MUT) IGF1R 30UTR construct. Schematic illustration of sequence alignment between 30UTR of the IGF1R and seed-sequence of miR-
1275 is shown above the graph. Data are expressed as the mean ± SEM. Student’s t test was performed to compare each two groups. ***P < 0.001, **P < 0.01, *P < 0.05.
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the IGF2BPs, thus suppressing the viability, proliferation, migra-
tion, and clonogenicity of HuH-7 cells.
3.7. IGF1R is a direct target of miR-1275
Since a single microRNA can have multiple targets, it was
important to examine whether miR-1275 may also have a direct
regulatory effect on IGF1R mRNA. In silico analysis search results
yielded that miR-1275 is in fact predicted to target the IGF1R
30UTR. The binding region from the 30UTR of IGF1R was inserted
downstream to luciferase reporter gene in pmiRGLO vector to form
the IGF1R WT construct. A mutant construct was also prepared in
which the predicted binding region had been deleted. For IGF1RWT construct, luciferase activity was markedly inhibited when
cells were co-transfected with miR-1275 mimics (P = 0.0497,
respectively) (Fig. 5C), while no change was observed upon
co-transfection with miR-1275 inhibitors, or when the MUT con-
struct was co-transfected with miR-1275 mimics or inhibitors
(Fig. 5C). These ﬁndings indicate that miR-1275 directly binds to
the 30UTR of IGF1R.
4. Discussion
The dysregulation of microRNAs occurs frequently in many can-
cers including HCC, and, as post-transcriptional regulators of gene
expression, these small non-coding RNAs have been implicated in
cancer formation and progression [29]. The interest in microRNAs
2264 I.O. Fawzy et al. / FEBS Letters 589 (2015) 2257–2265as a therapeutic strategy stems from the ability of these endoge-
nous molecules to simultaneously control several aberrantly
expressed genes allowing for a multi-target therapy from a single
molecule. The IGF2BPs are a family of three highly homologous
mRNA-binding proteins which lock their target transcripts into a
speciﬁc conformation and control their transcriptional fate [30].
Their repertoire of target transcripts includes numerous
cancer-implicated genes and for this reason they present a promis-
ing approach for controlling cancer development [12,14,18–20]. By
bioinformatic analysis we predicted miR-1275 to simultaneously
target IGF2BP1, IGF2BP2, and IGF2BP3, a desirable property which
may bestow upon this microRNA the ability to indirectly regulate
many oncogenic transcripts through the control of these
mRNA-binding proteins. We found that miR-1275 is severely
underexpressed in HCC and cirrhotic liver from patients with
HCV-induced liver cancer. A previous study also identiﬁed
miR-1275 as a downregulated microRNA in HBV-associated HCC
[31]. This may imply that the underexpression of miR-1275 occurs
in malignant transformation of the liver regardless of the etiology.
Surprisingly few papers have reported the regulation of the
IGF2BPs by microRNAs, none of which have identiﬁed a single
microRNA which can simultaneously target all members of the
family. The present study, however, demonstrates that ectopic
expression of miR-1275 concomitantly reduces IGF2BP1, IGF2BP2,
and IGF2BP3 mRNA. Using microRNA-target expression constructs
it was demonstrated that all three IGF2BPs are the direct targets
of miR-1275.
Several lines of evidence implicate the IGF2BPs in cancer devel-
opment. An IGF2BP1-knockout mouse model displayed dwarﬁsm,
reduced viability, decreased cellular proliferation, and increased
apoptosis [32], while IGF2BP1 overexpression in adult female
transgenic mice led to very high incidence of tumors which were
generally multifocal, and several tumor-bearing mice had metas-
tases [33]. In vitro depletion of IGF2BP1 from multiple liver cancer
cell lines inhibited proliferation and induced apoptosis, which was
attributed to its ability to stabilize the c-MYC and MKI67 mRNAs
and increase c-Myc and Ki-67 protein expression, two potent reg-
ulators of cell proliferation and apoptosis [12]. Moreover, a murine
xenograft model with stably-depleted IGF2BP1 showed impaired
tumor growth [12]. The liver-speciﬁc overexpression of p62, a
splice variant of IGF2BP2 in which exon 10 is skipped, in mice
was demonstrated to strongly induce Igf2 expression [34];
similarly, in human hepatoma HepG2 cell lines, overexpression of
p62 led to increased IGF-2 and antiapoptotic effects [35]. Also,
depletion of IGF2BP3 in HCC cell line HA22T caused a decrease in
cell motility, invasion, and transendothelial migration [13].
Consistent with these other studies, we found that knockdown of
each of the three IGF2BPs severely impairs HuH-7 cell viability,
proliferation, migration, and colony-formation. Moreover, correct-
ing the expression of the dysregulated miR-1275 which suppresses
the IGF2BPs also led to similar effects. Due to its underexpression
in certain cancers, miR-1275 has previously been referred to as a
tumor-suppressor [31,36], however this is the sole study to per-
form comprehensive functional analysis experiments and portray
the net tumor suppressive effects of this microRNA in HCC.
Although many studies have focused on the role of IGF2BPs in
regulating IGF-2 transcripts, few studies have considered whether
IGF2BPs can inﬂuence the transcriptional fate of another crucial
member of the IGF axis, the IGF1R. A previous study overexpressed
the IGF2BPs and identiﬁed thousands of possible binding mRNAs,
and of note, IGF1R transcript was among the top 100 binding
mRNAs [37]. However, to date, the effects the IGF2BPs may have
upon binding to IGF1R mRNA in humans is unknown.
Findings of this study show for the ﬁrst time that knockdown
of IGF2BP1, 2, or 3 extensively reduces IGF1R protein, suggesting
that all three IGF2BPs act to enhance the protein levels of thisoncogenic receptor. Since IGF2BPs have been known to increase
protein levels of their targets either by enhancing translation or
by preventing degradation of the transcript, it was essential to
also assess their effects on the IGF1R mRNA. This study demon-
strates that silencing of each IGF2BP additionally leads to a
decrease in IGF1R transcript levels. Taken together with the previ-
ous RNA-immunoprecipitation study [37], this insinuates that
IGF2BPs may act to stabilize the IGF1R mRNA and/or shield it to
prevent its decay, as they have been reported to do for several
other target transcripts including CD44, CTNNB1, and KRAS
[19,38,39]. Interestingly, however, these ﬁndings are in partial
disagreement with a study conducted on murine myoblasts,
which found that knockdown of IGF2BP2 reduced IGF1R protein
yet did not signiﬁcantly change the level of Igf1r mRNA [40].
The effect of an IGF2BP on its target transcript may be dependent
on its phosphorylation status, the recruitment of other regulatory
proteins to the complex, or cis-determinants in the target tran-
script [4,10,41]. Therefore the incongruities observed between
the two studies may be attributable to species or cell-type differ-
ences, or to several aforementioned factors which may inﬂuence
the function of the IGF2BPs.
We found that similar to the effects of knocking down the
IGF2BPs, forcing the expression of miR-1275 also results in a
considerable decrease in IGF1R mRNA and protein. Additionally,
in silico analysis revealed a binding region for miR-1275 in the
30UTR of the IGF1R transcript and luciferase activity assays demon-
strated that IGF1R is a direct target of miR-1275. Hence, it can be
construed that miR-1275 not only directly targets the IGF1R, but
may also indirectly modulate IGF1R levels by controlling its
post-transcriptional regulators, the IGF2BPs.
In conclusion, we found that miR-1275 is downregulated in
cirrhotic and cancerous liver tissues, and forcing its expression
suppresses the IGF2BPs and effectively impairs tumor cell prolifer-
ation, migration, viability, and colony-formation. IGF2BP1, IGF2BP2,
and IGF2BP3 were validated as direct targets for this microRNA.
Moreover we showed that knockdown of the IGF2BPs decreases
IGF1R mRNA and protein, and that IGF1R 30UTR is targeted by
miR-1275. Taken together, we demonstrated for the ﬁrst time that,
miR-1275 inhibits malignant cell behaviors by negatively regulat-
ing multiple oncogenic members of the IGF axis. Thus both
miR-1275 and its target genes, the IGF2BPs and the IGF1R, present
viable therapeutic targets for liver cancer.
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